Effect of α-Hemolysin Producing in Two Different Mouse Strains in a DSS Model of Inflammatory Bowel Disease

Overview

Journal Microorganisms

Specialty Microbiology

Date 2020 Dec 16

PMID 33322398

Citations 4

Authors

Hengameh Chloe Mirsepasi-Lauridsen

Carsten Struve

Andreas Munk Petersen

Karen Angeliki Krogfelt

Affiliations

Soon will be listed here.

Abstract

Background: Phylogroup B2 have been associated with ulcerative colitis (UC). In this study, we aimed to compare colonization with the UC-associated p19A in different mice strains, to investigate the role of alpha hemolysin in a UC mouse model.

Methods: In this study, Sigirr -/- and C57BL/6 mice were chosen, and UC was induced by adding dextran sulfate sodium (DSS) to the drinking water. The mice were pre-treated with ciprofloxacin. p19A expressing luminescence and GFP, alpha-hemolysin knock out p19A-ΔhlyI II, and non-pathogenic lab DH10B were cultured in LB broth, and orally gavaged into the mice. Colonization with p19A WT was visualized using an in vivo imaging system.

Results: p19A WT colonized the colon, ileum, Peyer's patches, liver, and spleen of infected C57BL/6 and Sigirr -/- mice. A total of 99% of the p19A WT infected C57BL/6 mice and 29% of the p19A WT infected Sigirr -/- mice survived to the 4th post infection day.

Conclusion: UC-associated p19A WT colonized the intestines of DSS-treated mice and caused extra-intestinal infection. Hemolysin is an important factor in this pathogenesis, since isogenic hemolysin mutants did not cause the same inflammation.

Citing Articles

Special Issue "Gastrointestinal Microbiota and Gut Barrier Impact Human Health and Disease": Editorial.

Raoul P, Cintoni M, Rinninella E, Mele M Microorganisms. 2023; 11(4).

PMID: 37110407 PMC: 10147068. DOI: 10.3390/microorganisms11040985.

Therapy Used to Promote Disease Remission Targeting Gut Dysbiosis, in UC Patients with Active Disease.

Mirsepasi-Lauridsen H J Clin Med. 2022; 11(24).

PMID: 36556089 PMC: 9784819. DOI: 10.3390/jcm11247472.

Role of adherent invasive in pathogenesis of inflammatory bowel disease.

Zheng L, Duan S, Dai Y, Wu S World J Clin Cases. 2022; 10(32):11671-11689.

PMID: 36405271 PMC: 9669839. DOI: 10.12998/wjcc.v10.i32.11671.

Substantial Intestinal Microbiota Differences Between Patients With Ulcerative Colitis From Ghana and Denmark.

Mirsepasi-Lauridsen H, Vranckx K, Nielsen H, Andersen L, Archampong T, Krogfelt K Front Cell Infect Microbiol. 2022; 12:832500.

PMID: 35372093 PMC: 8965593. DOI: 10.3389/fcimb.2022.832500.

References

Nuding S, Fellermann K, Wehkamp J, Stange E . Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut. 2007; 56(9):1240-7. PMC: 1954969. DOI: 10.1136/gut.2006.118646. View

Giaffer M, HOLDSWORTH C, Duerden B . Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut. 1992; 33(5):646-50. PMC: 1379295. DOI: 10.1136/gut.33.5.646. View

Vejborg R, Hancock V, Schembri M, Klemm P . Comparative genomics of Escherichia coli strains causing urinary tract infections. Appl Environ Microbiol. 2011; 77(10):3268-78. PMC: 3126446. DOI: 10.1128/AEM.02970-10. View

Xiao H, Gulen M, Qin J, Yao J, Bulek K, Kish D . The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity. 2007; 26(4):461-75. DOI: 10.1016/j.immuni.2007.02.012. View

Baumgart D, Sandborn W . Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369(9573):1641-57. DOI: 10.1016/S0140-6736(07)60751-X. View

Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M . Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis. 2010; 50(4):473-80. DOI: 10.1086/649923. View

Bucker R, Schulz E, Gunzel D, Bojarski C, Lee I, John L . α-Haemolysin of Escherichia coli in IBD: a potentiator of inflammatory activity in the colon. Gut. 2014; 63(12):1893-901. DOI: 10.1136/gutjnl-2013-306099. View

Png C, Linden S, Gilshenan K, Zoetendal E, McSweeney C, Sly L . Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010; 105(11):2420-8. DOI: 10.1038/ajg.2010.281. View

Bortolussi R, Ferrieri P, Wannamaker L . Dynamics of Escherichia coli infection and meningitis in infant rats. Infect Immun. 1978; 22(2):480-5. PMC: 422181. DOI: 10.1128/iai.22.2.480-485.1978. View

10.

Kinnebrew M, Pamer E . Innate immune signaling in defense against intestinal microbes. Immunol Rev. 2011; 245(1):113-31. PMC: 4624287. DOI: 10.1111/j.1600-065X.2011.01081.x. View

11.

Matricon J, Barnich N, Ardid D . Immunopathogenesis of inflammatory bowel disease. Self Nonself. 2011; 1(4):299-309. PMC: 3062384. DOI: 10.4161/self.1.4.13560. View

12.

Mirsepasi-Lauridsen H, Halkjaer S, Mortensen E, Lydolph M, Nordgaard-Lassen I, Krogfelt K . Extraintestinal pathogenic Escherichia coli are associated with intestinal inflammation in patients with ulcerative colitis. Sci Rep. 2016; 6:31152. PMC: 5043179. DOI: 10.1038/srep31152. View

13.

Mirsepasi-Lauridsen H, Vallance B, Krogfelt K, Petersen A . Pathobionts Associated with Inflammatory Bowel Disease. Clin Microbiol Rev. 2019; 32(2). PMC: 6431131. DOI: 10.1128/CMR.00060-18. View

14.

Newman B, Siminovitch K . Inflammatory bowel disease: Crohn's disease and the success of NODern genetics. Clin Invest Med. 2003; 26(6):303-14. View

15.

Gibson D, Ma C, Rosenberger C, Bergstrom K, Valdez Y, Huang J . Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell Microbiol. 2007; 10(2):388-403. DOI: 10.1111/j.1462-5822.2007.01052.x. View

16.

Hua S, Marks E, Schneider J, Keely S . Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015; 11(5):1117-32. DOI: 10.1016/j.nano.2015.02.018. View

17.

Goyal N, Rana A, Ahlawat A, Bijjem K, Kumar P . Animal models of inflammatory bowel disease: a review. Inflammopharmacology. 2014; 22(4):219-33. DOI: 10.1007/s10787-014-0207-y. View

18.

Sham H, Shames S, Croxen M, Ma C, Chan J, Khan M . Attaching and effacing bacterial effector NleC suppresses epithelial inflammatory responses by inhibiting NF-κB and p38 mitogen-activated protein kinase activation. Infect Immun. 2011; 79(9):3552-62. PMC: 3165486. DOI: 10.1128/IAI.05033-11. View

19.

Kotlowski R, Bernstein C, Sepehri S, Krause D . High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut. 2006; 56(5):669-75. PMC: 1942160. DOI: 10.1136/gut.2006.099796. View

20.

Sartor R . Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004; 126(6):1620-33. DOI: 10.1053/j.gastro.2004.03.024. View